Panacea Biotec’s stock jumped after the company announced that it has completed enrollment for the Phase III trial of its dengue vaccine, DengiAll where over 10,000 participants joined the study. Panacea Biotec developed the vaccine in collaboration with ICMR, and they will be monitoring the results for the next two years. DengiAll is expected to reach the market by 2027.